Accucaps Industries Ltd., a drug manufacturing company with offices in Ontario, has been sold to American pharmaceutical company Catalent Inc.
The acquisitionwill substantially complement Catalent’s global OTC and prescription pharmaceutical softgel capabilities and capacity with the addition of a portfolio of products supplied to pharmaceutical companies in North America, and two state-of-the-art facilities offering integrated softgel development, manufacturing and packaging, strengthening Catalent’s ability to offer customers turnkey solutions.
Moreover, as a result of the deal, Accucaps’ more than 500 employees will be joining Catalent’s global network of 11 softgel technologies facilities.
“Significant investments already made by Accucaps align well with Catalent’s own strategic goals, to offer our customers access to more products, capacity, and integrated solutions for differentiated products and better treatments,” says Aris Gennadios, Catalent’s president of softgel technologies.
